Illumina Cybersecurity Vulnerability May Present Risks for Patient Results and Customer Networks: Letter to Health Care Providers

---

Today, the U.S. Food and Drug Administration (FDA) issued a Letter to Health Care Providers about a cybersecurity vulnerability affecting the Illumina NextSeq 550Dx, MiSeqDx, NextSeq 500, NextSeq 550, MiSeq, iSeq, and MiniSeq next generation sequencing instruments.

READ  MORE:  https://www.fda.gov/medical-devices/letters-health-care-providers/illumina-cybersecurity-vulnerability-may-present-risks-patient-results-and-customer-networks-letter?utm_medium=email&utm_source=govdelivery

The Letter to Health Care Providers includes important information about this cybersecurity vulnerability, including:

• Background on the issue and the FDA’s actions to address it.
• Recommendations on how to mitigate cybersecurity risks associated with NextSeq 550 DX, MiSeqDX, NextSeq 500, NextSeq 550, MiSeq, iSeq, and MiniSeq sequencing instruments.
• Instructions for reporting problems to the FDA about this cybersecurity vulnerability.

Questions?

If you have questions about this letter to health care providers, contact the Division of Industry and Consumer Education (DICE).

---

This information has been broadcast to: Blood Banks; Community Health Centers (FQHCs); Emergency Medical Services / First Responders; Long-term Care; Health Care Facilities / Other; Health Care Organizations; Health Care Providers; Hospital Staff Directory; Hospital CEOs; Hospital Emerg Preparedness Coords; Hospital ER Medical Directors; Hospital Infection Control Practitioners; Hospital Medical Directors; Hospital Nursing Directors; Hospital Security Directors; ICU Administrator; Lab Director; Hospitals / Acute Care; Hospitals / Other; Hospitals / Veterans; Labs / Non-Sentinel; Labs / Sentinel; Occupational Health Organizations; Pharmaceutical Suppliers; Local Boards of Health; NJDOH Staff; NJLINCS and Local Contacts; NJLINCS Community; Public Health Associations; Public Health Council; Public Health Sector